AInvest★★★★★3-DAY FREE

Catch pre-market movers with AI signals.

Claim Trial
goodbyclunky - Author Avatar

goodbyclunky

goodbyclunky
goodbyclunky Yesterday
$QCOM disappointing it's not doing wellQCOM--
Savings-Valuable-265
Savings-Valuable-265 Yesterday

Does this change my 5-year QCOM thesis?

wcchurning
wcchurning Yesterday

In semis, how does QCOM’s miss compare to NVDA and AMD growth? Is this just memory cycle softness or broader demand?

Shakyhedgehog
Shakyhedgehog Yesterday

Reading this, it sounds like QCOM missed guidance and growth was softer than expected, even if revenue was okay. Feels like investors want faster growth, and the market’s getting frustrated.

goodbyclunky
goodbyclunky Yesterday
$TOST one day profits will come hereTOST--
goodbyclunky
goodbyclunky Yesterday
$SOXS who needs food and gas when we can make chips and build a data centerSOXS--
goodbyclunky
goodbyclunky Yesterday
$META was excited until the delusion news. Get rid of that idiot zuckMETA--
goodbyclunky
goodbyclunky Yesterday
$F considered taking profits but I believe F is just beginning. No FOMOF--
goodbyclunky
goodbyclunky 06/07
$PLTR It's time to soar again lolPLTR--
Critical-Peace-8319
Critical-Peace-8319 06/07

Trend’s up; riding PLTR until it stalls.

factsandgrow
factsandgrow 06/07

Trimming PLTR, adding cash until trend stabilizes.

Overlord1317
Overlord1317 06/07

Seen this movie—trendy stocks fade fast, right?

goodbyclunky
goodbyclunky 06/07
$NVAX The Verdict: It's a "Turnkey" Phase 3 Asset Management’s verbal tightrope—refusing to say "this guarantees approval" while still pushing its big partner value—is smart. If they claim it's 100% on its own, it sets a risky expectation for Wall Street, and if the FDA asks for even a small extra safety group, the stock tanks. But if they say it's just a regular exploratory phase, they lose their edge in licensing talks. By gathering safety data from over 9,000 patients and running formal lot-consistency tests, Novavax has built a ready-to-go asset. Whether they file it themselves or hand it off to a big pharma partner to finish it, the data is designed to meet regulatory standards, not textbook requirements. I think we'll hear about our CIC progress and get news on a partner.NVAX--
goodbyclunky
goodbyclunky 06/07
$DJT because you put God in a box that's exactly itDJT--
goodbyclunky
goodbyclunky 06/07
$KORU $INOD $SPY $QQQ Kospi tends to mirror $KORU $EWY Fridays near the close, possibly leading to a sharp drop.EWY--
INOD--
KORU--
QQQ--
SPY--
Scroll to load more